PDS Biotechnology Corp

PDS Biotechnology Corporation is a clinical-stage immunotherapy company that develops targeted cancer and infectious disease immunotherapies. The company's pipeline is based on its Versamune® T cell activator and Versamune® in combination with its interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. Additionally, the company is developing the Infectimune® T cell-activator for infectious diseases. Versamune® immunotherapies and Versamune® in combination with PDS01ADC are being developed for oncology treatments. Infectimune® is being developed for preventive vaccines against infectious agents. When paired with an antigen, Versamune® and Infectimune® have been shown to induce, in-vivo, large quantities of high-quality, highly potent polyfunctional disease-specific CD4 helper and CD8 killer T cells. Infectimune® is also designed to promote the induction of disease-specific neutralizing antibodies. PDS01ADC is an investigational tumor targeting IL-12. In September 2024, the company announced updated data from its VERSATILE-002 Phase 2 clinical trial at the European Society for Medical Oncology (ESMO) Congress 2024. In October 2024, the company announced updated data from the IMMUNOCERV Phase 2 clinical trial evaluating PDS0101 with chemoradiation to treat locally advanced cervical cancer at the American Society for Radiation Oncology (ASTRO) annual meeting 2024.